PDS5A

Sister chromatid cohesion protein PDS5 homolog A · Q29RF7 · PDS5A on Sugi Atlas →

0 patent compounds predicted against PDS5A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PDS5A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phenoxybenzamine Versus Doxazosin in PCC Patients PHASE4COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment PHASE2/PHASE3RECRUITING
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects PHASE1/PHASE2COMPLETED
Phase II Study of Olaparib and Pembrolizumab in Advanced Melanoma With Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation PHASE2UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma PHASE2ACTIVE_NOT_RECRUITING
PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors PHASE1/PHASE2NOT_YET_RECRUITING
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis PHASE2ACTIVE_NOT_RECRUITING
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy PHASE2COMPLETED
Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and AMD3100 PHASE1/PHASE2COMPLETED
Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial) PHASE2UNKNOWN
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel PHASE1COMPLETED
Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w/ Refractory Cancer PHASE1COMPLETED
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers PHASE1RECRUITING
Better Delineation of CDK13 Related Phenotype and Epigenetic Signature. nanUNKNOWN
CDH1 Germline Mutations in Lobular Breast Cancer nanCOMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome nanACTIVE_NOT_RECRUITING
Endocrine Disruptors and Life STILe in Breast Cancer Development nanUNKNOWN
Quebec Pancreas Cancer Study nanUNKNOWN
Genetics of Prostate Cancer in Young Patients nanCOMPLETED
PCD New Gene Discovery nanCOMPLETED
Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease nanUNKNOWN
Identification of Prostate Cancer Genes nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms nanUNKNOWN
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a PDS5A binder may also engage these)

ProteinNameSimilarity
A4L9P7 1.000 A4L9P7 →
Q6A026 1.000 Q6A026 →
Q5F3V3 1.000 Q5F3V3 →
A1L1F4 1.000 A1L1F4 →
Q5F3U9 1.000 Q5F3U9 →
Q6TRW4 1.000 Q6TRW4 →
Q498H0 1.000 Q498H0 →
Q4VA53 1.000 Q4VA53 →
Q4QXM3 1.000 Q4QXM3 →
Q4KLU7 1.000 Q4KLU7 →
Q5U241 1.000 Q5U241 →
PDS5B Sister chromatid cohesion protein PDS5 homolog B 1.000 landscape →
ECPAS Proteasome adapter and scaffold protein ECM29 0.990 landscape →
Q5R6J0 0.990 Q5R6J0 →
C0H906 0.988 C0H906 →
P42346 0.987 P42346 →
Q6GQD0 0.987 Q6GQD0 →
Q6GQ80 0.987 Q6GQ80 →
Q6PDI5 0.987 Q6PDI5 →
F1R2X6 0.986 F1R2X6 →
Q9BPX3 0.986 Q9BPX3 →
MTOR Serine/threonine-protein kinase mTOR 0.986 landscape →
Q56A27 0.985 Q56A27 →
F1MKX4 0.985 F1MKX4 →
Q9JLN9 0.985 Q9JLN9 →
Q6DDM4 0.985 Q6DDM4 →
B3NU52 0.984 B3NU52 →
Q5ZMW3 0.984 Q5ZMW3 →
Q6DIE2 0.984 Q6DIE2 →
Q7PX35 0.984 Q7PX35 →